sorafenib (MultiTarget Pharmaceuticals)
Structured Review
Sorafenib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitarget/sorafenib/pm40356522-579-5-12
Average 90 stars, based on 1 article reviews
Images
Related Articles
Clinical Proteomics:Article Title: The Osgin Gene Family: Underexplored Yet Essential Mediators of Oxidative Stress Article Snippet: .. Migration:Article Title: Insights into the mechanisms of angiogenesis in hepatoblastoma Article Snippet: .. It is a multitarget tyrosine kinase inhibitor (inhibiting VEGFR2/3, PDGFR, etc.) and is currently used to treat adult and pediatric hepatocellular carcinoma, but the efficacy of other:Article Title: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma Article Snippet: |
![Screening potential candidates of TET-family inhibitors in infected hiPSC-CMs via computational molecular docking simulation. (A) The flowchart of the drug screening platform for molecular docking analysis of TET2 in complex with its DNA substrate and representative inhibitors. (B) Schematic representation of the molecular docking of representative TET2 <t>inhibitors—Bobcat339,</t> TFMB-2HG, and TETi76—into the catalytic pocket of TET2. The figure illustrates the catalytic core of TET2 binding to methylated DNA, followed by computational screening and docking of small-molecule inhibitors into the active site. (C) TET2 in complex with DNA substrate (Protein Data Bank [PDB] ID: 7NE3). Left: Overall structure showing TET2 (ribbon representation) bound to DNA (sticks in orange and magenta). Middle: Close-up view of the catalytic pocket highlighting the interaction surface. Right: 2-dimensional (2D) interaction diagram illustrating contacts between TET2 and the DNA substrate. (D) TET2 in complex with TETi76. Left: Chemical structure of TETi76. Middle: Docked pose of TETi76 in the TET2 catalytic site. Right: 2D interaction diagram showing hydrogen bonding and hydrophobic contacts. (E) TET2 in complex with Bobcat339. Left: Chemical structure of Bobcat339. Middle: Docked binding mode of Bobcat339 in the catalytic site. Right: 2D interaction map illustrating hydrogen bonds, hydrophobic interactions, and halogen bonding. (F) TET2 in complex with TFMB-2HG. Left: Chemical structure of TFMB-2HG. Middle: Docked pose within the TET2 active site. Right: 2D interaction map showing hydrogen bonding and minimal hydrophobic interactions.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0876/pmc12280876/pmc12280876__bmr.0229.fig.005.jpg)
